Keywords: GlaxoSmithKline, Votrient, UK launch, Renal cell carcinoma, Least developed countries, Medicines access

GlaxoSmithKline’s Votrient now launched in UK for renal cell carcinoma; firm to expand drug access to poorest countries

Article | 06 July 2010

Print This

GlaxoSmithKline announced on Friday that Votrient (pazopanib) is now available in the UK for the first-line treatment of patients with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in